Arbutus Launches $230 Million Dutch-Auction Share Tender

Arbutus Biopharma Corporation has launched a modified Dutch-auction tender offer to buy and cancel up to $230 million of its common shares, giving investors the choice to sell stock back to the company within a price range of $5.00 to $5.75 per share. The offer began Aug. 24 and is scheduled to expire at 5:00 p.m. New York City time on Sept. 29 unless Arbutus extends or withdraws it.

The potential repurchase is large relative to Arbutus’ share base. The company had 198,105,743 common shares outstanding as of Aug. 19. If the offer is fully subscribed, Arbutus says it would buy about 46 million shares at the bottom of the range or 40 million at the top, equal to roughly 23.2% or 20.2% of the shares then outstanding. Arbutus closed at $5.21 on Nasdaq on Aug. 21, the last full trading day before the tender began, placing the announced range both below and above that reference price.

The company’s SEC-filed offer documents make clear that the final price will not simply be chosen in advance. Shareholders can tender at specific prices, accept the price ultimately determined by the auction, or use a proportionate tender designed to preserve their percentage ownership after the repurchase. Arbutus will then establish one purchase price for all shares accepted under the offer.

How the Dutch auction will set the buyback price

Under the first method, shareholders can submit auction tenders at prices between $5.00 and $5.75 in $0.05 increments. A second method, called a purchase-price tender, lets an investor submit a specified number of shares without naming a price. For purposes of determining the clearing price, those shares are treated as though they were tendered at the $5.00 minimum. A third option allows a shareholder to make a proportionate tender, agreeing to sell enough shares at the final purchase price to maintain the same percentage ownership after the offer is completed.

After the Sept. 29 deadline, Arbutus plans to set the lowest single price that allows it to purchase the eligible auction and purchase-price shares within the amount available to those tenders after accounting for proportionate tenders. Shares offered at an auction price above the final purchase price will not be bought. Shares accepted at or below the clearing level, including shares submitted through purchase-price tenders and valid proportionate tenders, will all receive the same per-share price, subject to the offer’s terms and applicable withholding taxes.

If eligible tenders exceed the available amount, the rules provide preferential treatment for shareholders who own fewer than 100 shares and tender all of them at or below the purchase price. Remaining eligible auction and purchase-price tenders would then be accepted on a pro rata basis. Arbutus also obtained U.S. and Canadian regulatory relief needed for the proportionate-tender feature and certain extension mechanics.

That proportionate option is relevant because Roivant Sciences, Arbutus’ largest disclosed shareholder in the offer documents, beneficially owns 38,847,462 shares, or about 19.6% of the company as of Aug. 19. Roivant has told Arbutus that it intends to make a proportionate tender. Certain directors and officers, meanwhile, have indicated that they intend to tender up to an aggregate 682,630 shares through purchase-price tenders. Those intentions can change before the offer closes.

The tender is not conditioned on a minimum number of shares being submitted and does not depend on new financing. Arbutus expects to fund purchases, fees and expenses with available cash on hand. Assuming the deadline is not extended, the company says it expects to accept and pay for validly tendered shares on or about Oct. 2, or promptly thereafter. Payments are denominated in U.S. dollars, although shareholders may elect Canadian-dollar payment under the exchange provisions described in the offer documents.

Moderna settlement created the cash for the capital return

The buyback follows a sharp change in Arbutus’ balance-sheet position tied to its patent settlement with Moderna. At June 30, before the first settlement payment arrived, Arbutus reported $92.6 million of cash, cash equivalents and marketable securities. On July 8, it received $178.4 million as its share of a $950 million noncontingent payment made under the March settlement between Moderna, Arbutus and Genevant Sciences. The amount received by Arbutus included reimbursement of litigation costs.

The broader settlement has a stated value of up to $2.25 billion for Arbutus and Genevant together. Beyond the $950 million noncontingent payment, Moderna may owe an additional $1.3 billion if specified conditions involving a limited appeal under 28 U.S.C. §1498 are met. That contingent amount is not a guaranteed payment to Arbutus, and the settlement documents do not assign the entire figure to the company.

Arbutus also owns approximately 16% of Genevant and continues to anticipate a material dividend from that holding during the third quarter. The tender documents do not quantify the expected dividend. The board began evaluating ways to return capital in March, before the July payment was received, and considered both the Moderna proceeds and a potential Genevant distribution as part of its capital-allocation review.

In explaining the offer, the board said the tender provides a faster route to a sizeable repurchase than open-market buying under U.S. and Canadian securities rules. It also said recent trading did not, in its view, fully reflect the value of Arbutus’ business and future prospects. That valuation assessment is the company’s position, not an independent determination of fair value.

The capital return is occurring while Arbutus remains a clinical-stage biotechnology company rather than a mature cash-generating business. For the second quarter, it reported a net loss of $5.1 million on revenue of about $1.0 million. Research and development expense was $2.9 million and general and administrative expense was $3.9 million. Arbutus is preparing a proposed Phase 2b study of its chronic hepatitis B candidate imdusiran after reaching alignment with the U.S. Food and Drug Administration on study design and safety parameters, and it continues patent-enforcement actions with Genevant against Pfizer and BioNTech.

The board said that, after giving effect to the tender, it expects Arbutus to retain sufficient financial resources and working capital for ongoing operations and foreseeable business opportunities. That statement is forward-looking. The actual cash used will depend on the final purchase price, how many shares are tendered under each method and whether the offer’s conditions are satisfied.

A completed tender would materially shrink the share count

At full subscription, the repurchase would remove roughly one-fifth to nearly one-quarter of the Aug. 19 share count. The effect for investors who do not participate is straightforward: if shares are bought and cancelled, their proportional ownership of Arbutus increases because fewer common shares remain outstanding. Investors who tender, by contrast, receive cash for accepted shares and reduce or eliminate their continuing exposure depending on how much stock they sell.

The offer documents also address the effect on trading liquidity. Arbutus concluded, for purposes of Canadian securities requirements, that a liquid market existed when the offer was launched and that it was reasonable to expect a market for the remaining shares that would not be materially less liquid after completion. That is a regulatory and board assessment, not a guarantee about future trading conditions or the market price.

Neither Arbutus, its board, J.P. Morgan as dealer manager, nor the tender’s depositary and information agent is recommending that shareholders tender or hold their shares. The price range itself illustrates why the decision depends on an investor’s circumstances: the $5.00 floor is below the Aug. 21 closing price of $5.21, while the $5.75 ceiling is above it, and the eventual clearing price will not be known until after tenders are submitted.

The next fixed milestone is the Sept. 29 expiration at 5:00 p.m. New York City time, although brokers and other intermediaries may impose earlier internal deadlines. After expiration, Arbutus is expected to announce the purchase price and the number of shares accepted, with payment targeted for about Oct. 2 if the timetable is not extended and the offer’s conditions are met.